Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget

Cell Mol Immunol. 2020 Jul;17(7):677-679. doi: 10.1038/s41423-019-0348-4. Epub 2019 Dec 19.

Xing Huang^#^{1

2

3}, Xiaozhen Zhang^#^{1

2

3}, Xueli Bai^{4

5

6}, Tingbo Liang^{1

2

3}

¹ Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
² Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
³ Innovation Center for the Study of Pancreatic Diseases, Zhejiang Province, Hangzhou, 310003, Zhejiang, China.
⁴ Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China. shirleybai@zju.edu.cn.
⁵ Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China. shirleybai@zju.edu.cn.
⁶ Innovation Center for the Study of Pancreatic Diseases, Zhejiang Province, Hangzhou, 310003, Zhejiang, China. shirleybai@zju.edu.cn.

^# Contributed equally.

No abstract available

Publication types